https://f2g.com/ 2026-10-27T13:30:36+00:00 https://f2g.com/press-release/f2g-wins-investment-deal-of-the-year-bionow-2022-award/ 2023-04-30T14:30:39+00:00 https://f2g.com/press-release/f2g-to-present-at-biotech-showcase-2023/ 2023-04-30T14:30:57+00:00 https://f2g.com/press-release/f2g-announces-fda-filing-acceptance-of-new-drug-application-for-olorofim-for-the-treatment-of-invasive-fungal-infections/ 2023-04-30T14:30:57+00:00 https://f2g.com/press-release/f2g-announces-data-from-phase-2b-study-at-id-week-2022-showing-positive-therapeutic-response-in-patients-with-invasive-fungal-infections-treated-with-olorofim/ 2023-04-30T14:30:57+00:00 https://f2g.com/press-release/f2g-to-present-interim-results-from-phase-2b-open-label-study-of-olorofim-in-invasive-fungal-infections-at-idweek-2022/ 2023-04-30T14:30:57+00:00 https://f2g.com/press-release/f2g-announces-70-million-financing-to-advance-development-and-commercialization-of-new-antifungal-agent-olorofim/ 2023-04-30T14:30:57+00:00 https://f2g.com/press-release/shionogi-co-ltd-and-f2g-enter-strategic-collaboration-to-develop-and-commercialize-the-new-antifungal-agent-olorofim-in-europe-and-asia/ 2023-04-30T14:30:57+00:00 https://f2g.com/press-release/clinical-stage-rare-disease-biotech-f2g-appoints-new-non-executive-director-and-two-senior-executives-ahead-of-pivotal-year/ 2023-04-30T14:30:58+00:00 https://f2g.com/press-release/f2g-appoints-camilla-soenderby-to-board-of-directors/ 2023-04-30T14:30:58+00:00 https://f2g.com/press-release/francesco-maria-lavino-appointed-chief-executive-officer-of-f2g-ltd/ 2023-04-30T14:30:58+00:00 https://f2g.com/press-release/f2g-receives-second-us-fda-breakthrough-therapy-designation-for-olorofim/ 2023-04-30T14:30:58+00:00 https://f2g.com/press-release/f2g-closes-us60-8-million-financing-to-fund-late-stage-development-of-novel-mechanism-antifungal-agent/ 2023-04-30T14:30:58+00:00 https://f2g.com/press-release/f2gs-olorofim-receives-both-fda-orphan-drug-designation-for-coccidioidomycosis-valley-fever-and-fda-qidp-designation-for-multiple-fungal-infections/ 2023-04-30T14:30:58+00:00 https://f2g.com/press-release/f2g-receives-us-fda-orphan-drug-designation-for-olorofim/ 2023-04-30T14:30:58+00:00 https://f2g.com/press-release/f2g-receives-us-fda-breakthrough-therapy-designation-for-olorofim/ 2023-04-30T14:30:58+00:00 https://f2g.com/press-release/f2g-appoints-dr-patrick-vink-as-chairman/ 2023-04-30T14:30:59+00:00 https://f2g.com/press-release/f2g-is-a-recipient-of-the-2019-eib-innovation-award/ 2023-04-30T14:30:59+00:00 https://f2g.com/press-release/f2g-expands-investor-syndicate-and-progresses-phase-iib-study-for-novel-antifungal/ 2023-04-30T14:30:59+00:00 https://f2g.com/press-release/eu-supports-f2g-biotech-in-austria-with-eur-24-million-for-antifungal-research-and-innovation/ 2023-04-30T14:30:59+00:00 https://f2g.com/press-release/f2g-ltd-receives-european-orphan-drug-designation-for-its-lead-candidate-f901318/ 2023-04-30T14:30:59+00:00 https://f2g.com/press-release/f2g-ltd-announces-the-appointment-of-john-h-rex-md-facp-to-the-position-of-chief-medical-officer/ 2023-04-30T14:31:11+00:00 https://f2g.com/press-release/f2g-ltd-announces-publication-of-initial-f901318-data-in-scientific-journal-pnas/ 2023-04-30T14:31:11+00:00 https://f2g.com/press-release/f2g-ltd-announces-the-appointment-of-ralf-schmid-to-the-position-of-chief-financial-officer/ 2023-04-30T14:31:12+00:00 https://f2g.com/press-release/f2g-ltd-announces-60-million-financing-to-progress-development-of-novel-antifungal-agents/ 2023-04-30T14:31:12+00:00 https://f2g.com/press-release/f2g-receives-complete-response-letter-from-fda-for-new-drug-application-for-olorofim-for-the-treatment-of-invasive-fungal-infections-plans-resubmission-with-additional-data-and-analyses/ 2023-08-08T10:34:05+00:00 https://f2g.com/press-release/f2g-moves-uk-headquarters-to-mediacity/ 2023-08-08T10:37:41+00:00 https://f2g.com/press-release/f2g-announces-100-million-financing-to-advance-late-stage-development-and-commercialization-of-novel-antifungal-drug-candidate-olorofim-in-the-us/ 2024-09-11T16:10:34+00:00 https://f2g.com/press-release/f2g-announces-publication-in-the-lancet-infectious-diseases-of-phase-2b-data-demonstrating-positive-therapeutic-responses-in-patients-with-serious-invasive-fungal-diseases-treated-with-oral-olorofim/ 2026-06-18T08:04:13+00:00 https://f2g.com/press-release/f2g-and-shionogi-announce-positive-topline-results-from-global-phase-3-oasis-study-evaluating-oral-olorofim-versus-ambisome-followed-by-standard-of-care-in-patients-with-invasive-aspergillosis-2/ 2026-06-18T09:18:21+00:00 https://f2g.com/press-release/f2g-announces-posters-accepted-for-presentation-at-upcoming-medical-meetings/ 2026-09-03T13:48:22+00:00 https://f2g.com/press-release/f2g-announces-abstracts-accepted-for-oral-and-poster-presentation-at-idweek-2026/ 2026-10-05T10:43:29+00:00 https://f2g.com/press-release/f2g-and-shionogi-report-data-from-global-phase-3-oasis-study-evaluating-investigational-oral-olorofim-versus-ambisome-followed-by-standard-of-care-in-invasive-aspergillosis-in-late-breaking-oral/ 2026-10-21T08:33:18+00:00